ZIOPHARM receives European patent for Palifosfamide
The patent covers pharmaceutical compositions of a DNA cross-linker (stabilized active metabolite of ifosfamide), including palifosfamide (Zymafos or ZIO-201) and their use in treating cancer. The company has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.